drugset / Trial / NCT07355764
MA-CRC-II-016 SHR-1811
RandomizedFactorialSingle-blindTreatment
Summary
A randomized, controlled, multicenter clinical study of SHR-A1811 combined with bevacizumab for the second-line treatment of metastatic colorectal cancer
Timeline
- Start
- 2025-12-30
- Primary completion
- 2028-01-30
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Trastuzumab Rezetecan | Monoclonal antibody | — | — |
| Comparator | SHR-A1811 & Bevacumab injection | Unknown | — | — |